Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Q1 net loss widens to $15.8 million on $13.5 million impairment

Negative Impact 4 of 5 earnings Written later

Grace Therapeutics reported a net loss of $15.8 million, or $0.91 per share, for the three months ended June 30, 2026, up from $3.4 million, or $0.21 per share, a year earlier. The increase was mainly due to a $13.5 million impairment of in-process research and development tied to GTx-101 and GTx-102, which the company deprioritized in favor of GTx-104. The company also said cash and cash equivalents were $22.2 million as of August 11, 2026, and that existing cash is expected to last through the end of calendar 2028.

Key points

  • Net loss of $15.8 million, or $0.91 per share, versus $3.4 million, or $0.21 per share, in the same period of 2025
  • $13.5 million impairment of IPR&D for GTx-101 and GTx-102; no impairment was recorded for GTx-104 in the quarter
  • Cash and cash equivalents of $22.2 million as of August 11, 2026, with cash runway expected through the end of calendar 2028
  • Company announced a $10 million private placement and said it is pursuing a dual-source manufacturing strategy for the GTx-104 NDA resubmission

The filing

CompanyGrace Therapeutics, Inc. (GRCE)
Form8-K, current report
Filed with the SECAug 13, 2026, 8:01 AM ET
Accession number0001140361-26-032644

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.